Tagged with EY

Turkey Turkey’s pharma market, the 18th largest in the world and valued at USD 7 Billion in 2020, has seen steady growth over the past few years due to favorable healthcare reforms and increased government support. According to a new report from Invest in Turkeye, in 2020 the country accounted for…

Global Not very long ago, no one had heard of monkeypox, but the disease has now extended to 21 countries in the world. Apart from the existing smallpox vaccines, which have proven to be effective against it, Moderna plans to explore new vaccines. Monkeypox, a zoonotic virus that mainly spreads among…

Korea Two decades ago, South Korean company Celltrion embarked on a quest to find the necessary resources to produce biopharmaceuticals. It took five years for their manufacturing plant to receive GMP certification from the US FDA in 2007 and another one to launch an initial public offering; an ascent that, while…

Global Drawing on the findings of EY’s recently published life sciences M&A firepower report, EY Global Life Sciences Deals Leader Subin Baral makes the case for big biopharmas to seek out alliances and partnerships as an alternative to M&A and lists ten considerations that these firms should bear in mind if…

Denmark Denmark boasts plenty of strong fundamentals as a clinical trials hub, but is perhaps constrained by a population of just 5.8 million and a correspondingly small patient pool. However, international collaboration, not least with neighbouring Sweden (population 10.4 million), has the potential to greatly increase the pool from which trial…

Turkey With an already well-established manufacturing industry for pharmaceuticals, Turkey has been aiming to move with global trends and invest in biologics production, specifically in biosimilars.   The share of biotechnological pharmaceuticals has reached 30 percent globally, a rate that is expected to continue increasing, but the market share in Turkey…

Turkey Becoming the clinical trials country leader in the region has been set as a primary goal for Turkey’s pharma industry to achieve global competitiveness. The government’s strategy is to increase its share of global clinical studies both in numbers and investment. Today, the country occupies the 26th position with 529…

Turkey Few Turkish companies are experiencing such a transformational moment as GEN. In 2021 alone, the Ankara-based organization made its public debut on the Istanbul Stock Exchange and signed an exclusive collaboration agreement with Dutch biotech Sulfateq BV for the development and commercialization of a therapy against Alzheimer’s and other neurodegenerative…

Turkey When the Turkish Ministry of Health implemented its strategy to transition from import pharmaceuticals to manufacturing them at home in 2016, the local industry leveraged the situation to invest in new technology and increase their manufacturing capacity. A few multinational innovators took the opportunity to invest in their own plants,…

Turkey As an upper-middle-income country with an emerging economy, Turkey could not invest billions in COVID-19 vaccine R&D, but a strong research ecosystem and willing industry allowed it to kickstart multiple vaccine and drug projects, discovering a new collaborative model along the way.   The responsibility for coordinating Turkey’s research and…

Turkey Overseeing healthcare for a population of over 80 million, Turkey’s Ministry of Health was put under the spotlight during the COVID-19 pandemic. Here, we highlight four of the hot-button items on Minister of Health Dr Fahrettin Koca’s plate as Turkey emerges from the pandemic period.   Pandemic Learnings A few…

Turkey There are perhaps no two words that better summarize the last few years in Turkish pharma than localization and pricing. But after years of investment and struggles, the country’s priorities appear to be shifting. Turkey’s Vision 2023, as defined in its 11th Development Plan, has changed the government’s vision regarding…